Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. The investigation concerns whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On September 29, 2025, Larimar disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants in a study of nomlabofusp, causing its stock price to fall $1.72 per share, or 33.66%, to close at $3.38 per share. Then, on June 29, 2026, Larimar revealed an ongoing safety signal with anaphylaxis reported in 10 of 43 patients, leading to a stock price drop of $0.46 per share, or 12.57%, to close at $3.20 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
Larimar Therapeutics IncSecurities fraud investigation and safety signal disclosures causing stock price drops.